Endocrine Abstracts

Nonfunctioning pituitary macroadenomas are benign tumors, characterized by the clinical and biochemical absence of hormonal overproduction. Clinical symptoms are mainly caused by mass effects of the tumor. The main symptoms are pituitary insufficiencies, visual field defects, decreased visual acuity and headache. For nonfunctioning adenomas with a diameter of less than one cm no treatment is necessary. In patients with a nonfunctioning macroadenoma without visual field defects...

Background: Type 2 diabetes (T2D) and hypercortisolism associated with Cushing’s syndrome (CS) share clinical characteristics such as hypertension, dyslipidaemia, hyperglycaemia, and obesity. Several studies have recorded a relatively high prevalence of hypercortisolism in T2D, which may have therapeutic implications. The aim of this systematic review and meta-analysis was to assess the prevalence of hypercortisolism in T2D patients.Methods: Origina...

Objective: To collect clinical and treatment outcome data in a large patient cohort, and specifically to report experience with temozolomide (TMZ).Design: Cohort study based on an electronic survey open for participation to ESE members Dec 2015-Nov 2016.Results: Reports on 167 patients, 40 pituitary carcinomas, and 127 aggressive pituitary tumours were obtained. Median age at diagnosis was 43 (range 4–79) years. 59% of tumours...

ObjectiveIn order to improve therapeutic outcomes for patients with acromegaly, new treatment algorithms have been developed over the last decades. Valid epidemiological data of acromegaly in Norway is lacking. The overall aim of this study was to investigate incidence, prevalence and mortality of acromegaly in South-Eastern Norway, and to investigate effects of new treatment algorithms.Design and methodPatie...

Background: Cross-sectional studies in small and selected populations indicate a relatively high prevalence of incipient and/or subclinical Cushing’s syndrome (CS) in patients with type 2 diabetes (T2D), which could have therapeutic implications.Aim: To estimate the prevalence of CS in a large, unselected cohort of recently diagnosed T2D patients.Methods: A total of 384 consecutive out – patients with T2D diagnosed after ...

Background: Hypercortisolism is prevalent in type 2 diabetes (T2D), but analytical and functional uncertainties prevail. Measurement of salivary cortisol is considered an expedient screening method for hypercortisolism, but its usefulness in the context of T2D is uncertain.Aim: To compare late night salivary cortisol (LNSC) with the 1 mg overnight dexamethasone suppression test (DST), which was considered ‘reference standard’, in T2D.<p cla...

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) was created in collaboration with the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Paediatric Endocrinology and the European Society of Endocrinology to support the needs of the endocrine community.Aim: To describe the patient population and data entered in the EuRRECa Core Registry between June 2019 and December 2021.<p class...

Background: Pancreatic Neuroendocrine Tumors (PanNETs) are highly prevalent in Multiple Endocrine Neoplasia type 1 (MEN1) and one of the main causes of mortality. Conventional imaging is the mainstay of PanNET screening/surveillance in MEN1. This study aims to assess the diagnostic accuracy of conventional pancreatic imaging studies and to determine the added value of pancreatic fine needle aspirations (FNA) for the diagnosis of MEN1-related PanNETs.Meth...

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) was created in collaboration with the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Paediatric Endocrinology and the European Society of Endocrinology to support the needs of the endocrine community. The Core Registry, one of its platforms, enables the collection of longitudinal patient and clinician reported outcomes. A module collecting aspects of the ...